Admissions:
Delistings:
Potential** Initial Public Offerings:
6 February: Media reports that The Beauty Tech Group, owner of CurrentBody, a brand of beauty technology, is considering a £350m London stock market listing. The Company describes itself as a global industry leader in home-use beauty technology, and is focused on products which use LED, radio frequency, microcurrent and laser treatments. The Beauty Tech Group saw revenues pass the £100m mark for the first time, up from £80m in 2023. Details, including the size of any primary share sale, have yet to be finalised.
6 February: GlobalData (DATA.L) has announced an intention to move to the Main Market from AIM. Timing is tbc.
6 February: Creightons (CRL.L) has announced an intention to move to AIM from the Main Market. Timing is subject to various approvals, but for 31 March.
All Things Considered 97.5p £16.1m (AQSE: ATC)
The independent music Company housing talent management, live booking, merchandising, talent services and events, provided an update on trading for the financial year ended 31 December 2024. FY24 delivered 100% growth in Group revenue to circa £50m (FY23: £24.1m) and profitability milestone surpassed with adjusted operating EBITDA anticipated to be approximately £1.5m (FY23: loss of £0.46m).
The Board of ATC is considering moving the public quotation for trading in its shares to a market operated by the LSE.
Cardiogeni 45p £38.4m (AQSE: CGNI)
The clinical stage biotechnology Company involved in heart failure medicines announced the signing of a memorandum of understanding with the Private Office of Sheikh Al Qassimi for direct investment and the funding of the Company's clinical trials. The funding will be through the formation of a joint venture with a total funding amount of £20m to complete research, development and clinical trials in the United Arab Emirates. The MoU includes £20m in funding in the period covering 2025 to 2027. £5m is coming via an initial investment in H125 with the remainder being supplied to fund the clinical development of Cardiogeni's heart failure medicines through Phase 2b/3 clinical trials.
Directa Plus 6.5p £6.8m (DCTA.L)
The producer and supplier of graphene-based products for use in consumer and industrial markets announces that Setcar, the Group's environmental subsidiary, has secured a new $1.5m contract win, with Midia International SA, and Euro 1.1m contract renewal, with Ford Otosan. Setcar initial agreement is to provide tank cleaning and waste disposal services as part of an offshore drilling campaign in the Black Sea, specifically the Trident EX30 block. Setcar renewed its contract with its long-standing client, Ford Otosan, for the sixth time, to deliver Total Waste Management services, including waste disposal, transportation, treatment, recycling, equipment, and personnel.
EnergyPathways 7.1p £12m (EPP.L)
The energy transition Company announced an update on its pre-Front End Engineering and Design (pre-FEED) activities for the Marram Energy Storage Hub (MESH) and the selected technical design for the initial phase of the MESH development. The technical engineering and design studies have been undertaken by EnergyPathways in conjunction with its strategic partners Wood plc, Mermaid Subsea Services (UK) Limited and PDi Ltd. The MESH development has been designed as an integrated energy system solution. MESH will connect gas production, gas storage, hydrogen storage, offshore wind and decarbonised gas power generation to provide the UK with a long term secure and dependable supply of clean energy.
EnSilica 49p £47.3m (ENSI.L)
The chip maker of mixed-signal ASICs (Application Specific Integrated Circuits) reports Interims to November 2024. Its Revenue at £9.3m is 3% lower, as was the Operating loss at £0.8m against break-even last time. There are four ASICs in production worth in aggregate £6m in FY25, which is double Y/E2024. Investment in IP and tooling of £2.6m was slightly lower although, there are five design and supply ASICs contracts won, generating supply revenues from 2027 onwards. These longer-term contracts include the automotive and industrial controller ASIC for more than $31m over seven years. The Telecommunications ASIC design and supply contract secured with SIAE Microelettronica is worth more than $30m over ten years. There is £8.1m of debt and working capital financing in place, with cash of £2.8m. The CEO reports that revenues from new contracts alone are expected to generate a further £100m over their lifetime, starting from 2027 onwards.
Filtronic 106p £232.1m (FTC.L)
The designer and manufacturer of products for the aerospace, defence, space and telecoms infrastructure markets announced a significant new contract win with SpaceX valued at $20.9m (£16.8m), to be fulfilled in both FY2025 and FY2026. Consequently, the Board is now confident the business will exceed current market expectations for revenue and profit in both FY2025 and FY2026.
Katoro Gold 0.00525p £0.8m (KAT.L)
The energy and precious minerals exploration and development Company announces a conditional equity financing of £317,500 at a placing price of 0.05p. Katoro also announced a heads of terms agreement (subject to the completion of the Placing) to acquire 100% of 31 Explore Ltd which controls an extensive portfolio of mining claims in Ontario, Canada. Katoro will acquire 31 Explore Ltd in exchange for warrants over ordinary shares.
Light Science Technologies 2.65p £8.6m (LST.L)
The Company focusing on the development and manufacturing of Contract electronic boards and lighting and technology products announces a distribution framework agreement with Gavita International. The agreement enables the Group to distribute lighting products developed by Gavita's subsidiary Agrolux Nederland, a global supplier of horticulture lighting solutions. The partnership's combined product offering will result in additional reach across the UK and in Europe (including Ireland), with current quoted pipeline opportunities totalling £4.6m and £5.7m, respectively, for provision of lighting systems to glass houses, increasing the Group's overall pipeline to £42.5m.
UK Oil & Gas 0.0185p £2.3m (UKOG.L)
The oil and gas Company announce that a workover campaign, culminating in the deeper seating of a downhole pump in Q4 2024, has achieved a significant increase in the Horndean field's production and resultant revenues (UKOG 10% interest). January 2025 full field production averaged 200 barrels of oil per day (bopd), 60% higher than the 125 bopd achieved in January 2024. As January 2025's 200 bopd average is already 19% above the 168 bopd 2025 annual field production forecast, further potential exists for increased 2025 production over the forecast.
Zinc Media Group 62p £15.1m (ZIN.L)
The television, brand and audio production Group made a trading update for Y/E December 2024. Revenue is £32m from continuing operations (FY23: £40m) reflecting portfolio changes, including the disposal and closure of non-core businesses during the year, as well as an acquisition and launch of an entertainment label, Electric Violet. These transactions focus the Group on its higher margin television and content production. Adjusted EBITDA increased by 50% to £1.5m, in line with market expectations. Gross cash is better than expected at £6.3m (£4.9m), following positive continued cash generation with £1.3m net cash. Momentum into the new year is reported to be “excellent”, with a record level of forward bookings driven by winning £16m of television production work in the last five months and there is a strong pipeline.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
